Abbott Laboratories ROA 2006-2019 | ABT
Current and historical return on assets (ROA) values for Abbott Laboratories (ABT) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Abbott Laboratories ROA for the three months ending June 30, 2019 was 7.83%.
| Abbott Laboratories ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2019-06-30 | $2.90B | $68.43B | 4.21% |
| 2019-03-31 | $2.62B | $67.61B | 3.82% |
| 2018-12-31 | $2.37B | $67.17B | 3.41% |
| 2018-09-30 | $0.89B | $71.64B | 1.23% |
| 2018-06-30 | $0.93B | $68.42B | 1.29% |
| 2018-03-31 | $0.48B | $70.91B | 0.66% |
| 2017-12-31 | $0.48B | $76.25B | 0.66% |
| 2017-09-30 | $2.10B | $72.25B | 3.15% |
| 2017-06-30 | $1.17B | $71.15B | 2.00% |
| 2017-03-31 | $1.50B | $70.89B | 2.96% |
| 2016-12-31 | $1.40B | $52.67B | 3.26% |
| 2016-09-30 | $1.37B | $39.50B | 3.42% |
| 2016-06-30 | $2.28B | $39.83B | 5.61% |
| 2016-03-31 | $2.45B | $39.64B | 5.87% |
| 2015-12-31 | $4.42B | $41.25B | 10.40% |
| 2015-09-30 | $4.56B | $41.73B | 10.72% |
| 2015-06-30 | $4.52B | $44.13B | 10.57% |
| 2015-03-31 | $4.20B | $43.10B | 9.99% |
| 2014-12-31 | $2.28B | $41.21B | 5.48% |
| 2014-09-30 | $1.97B | $42.51B | 4.67% |
| 2014-06-30 | $2.40B | $41.48B | 5.63% |
| 2014-03-31 | $2.41B | $41.66B | 5.61% |
| 2013-12-31 | $2.58B | $42.95B | 5.97% |
| 2013-09-30 | $3.04B | $44.13B | 6.17% |
| 2013-06-30 | $4.02B | $42.90B | 7.43% |
| 2013-03-31 | $5.27B | $42.69B | 8.96% |
| 2012-12-31 | $5.96B | $67.24B | 9.36% |
| 2012-09-30 | $6.53B | $63.26B | 10.54% |
| 2012-06-30 | $4.89B | $61.86B | 8.01% |
| 2012-03-31 | $5.11B | $62.42B | 8.36% |
| 2011-12-31 | $4.73B | $60.28B | 7.77% |
| 2011-09-30 | $4.55B | $59.63B | 7.47% |
| 2011-06-30 | $5.14B | $62.00B | 8.51% |
| 2011-03-31 | $4.49B | $61.65B | 7.71% |
| 2010-12-31 | $4.63B | $60.57B | 8.24% |
| 2010-09-30 | $4.73B | $57.37B | 8.72% |
| 2010-06-30 | $5.31B | $53.38B | 10.16% |
| 2010-03-31 | $5.31B | $53.36B | 10.44% |
| 2009-12-31 | $5.75B | $52.58B | 11.76% |
| 2009-09-30 | $5.74B | $49.85B | 12.39% |
| 2009-06-30 | $5.35B | $47.63B | 12.07% |
| 2009-03-31 | $5.38B | $45.44B | 12.39% |
| 2008-12-31 | $4.88B | $42.42B | 11.52% |
| 2008-09-30 | $4.55B | $41.75B | 10.91% |
| 2008-06-30 | $4.18B | $44.07B | 10.28% |
| 2008-03-31 | $3.85B | $41.18B | 9.89% |
| 2007-12-31 | $3.61B | $39.71B | 9.57% |
| 2007-09-30 | $1.93B | $37.62B | 5.24% |
| 2007-06-30 | $1.93B | $37.15B | 5.39% |
| 2007-03-31 | $1.55B | $36.29B | 4.43% |
| 2006-12-31 | $1.72B | $36.18B | 5.20% |
| 2006-09-30 | $3.17B | $33.30B | 10.14% |
| 2006-06-30 | $3.13B | $34.06B | 10.40% |
| 2006-03-31 | $3.40B | $28.53B | 11.89% |
| 2005-12-31 | $3.37B | $29.14B | 11.76% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $149.840B | $30.578B |
| Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $137.817B | 19.69 |
| Stryker (SYK) | United States | $81.180B | 28.07 |
| Boston Scientific (BSX) | United States | $58.714B | 28.48 |
| Baxter (BAX) | United States | $44.403B | 26.93 |
| EssilorLuxottica Societe Anonyme (ESLOY) | France | $30.829B | 0.00 |
| Zimmer Biomet Holdings (ZBH) | United States | $28.130B | 18.00 |
| Coloplast (CLPBY) | Denmark | $26.395B | 42.14 |
| Lonza Group Ag (LZAGY) | Switzerland | $26.038B | 0.00 |
| Terumo (TRUMY) | Japan | $23.788B | 27.35 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $20.267B | 0.00 |
| ResMed (RMD) | United States | $19.315B | 36.83 |
| Sunny Optical Technology (SNPTF) | China | $13.689B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.759B | 52.32 |
| Canopy Growth (CGC) | Canada | $9.745B | 0.00 |
| Insulet (PODD) | United States | $9.055B | 536.57 |
| William Demant Holdings (WILYY) | Denmark | $7.136B | 0.00 |
| Haemonetics (HAE) | United States | $7.033B | 53.07 |
| Hill-Rom Holdings (HRC) | United States | $7.032B | 20.97 |
| Perrigo (PRGO) | Ireland | $6.283B | 11.57 |
| Aurora Cannabis (ACB) | Canada | $6.094B | 59.90 |
| GN STORE NORD (GNNDY) | Denmark | $5.897B | 30.11 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.651B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $4.296B | 0.00 |
| Neogen (NEOG) | United States | $3.710B | 61.70 |
| ICU Medical (ICUI) | United States | $3.430B | 22.25 |
| NuVasive (NUVA) | United States | $3.316B | 26.44 |
| Hutchison China MediTech (HCM) | China | $2.737B | 0.00 |
| Quidel (QDEL) | United States | $2.552B | 25.34 |
| Agios Pharmaceuticals (AGIO) | United States | $2.491B | 0.00 |
| National Vision Holdings (EYE) | United States | $2.177B | 46.98 |
| Cardiovascular Systems (CSII) | United States | $1.682B | 0.00 |
| Aphria (APHA) | $1.551B | 0.00 | |
| Phibro Animal Health (PAHC) | United States | $1.263B | 18.92 |
| AtriCure (ATRC) | United States | $1.060B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.018B | 23.45 |
| NanoString Technologies (NSTG) | United States | $0.977B | 0.00 |
| Omeros (OMER) | United States | $0.967B | 0.00 |
| PetIQ (PETQ) | United States | $0.908B | 21.44 |
| Lantheus Holdings (LNTH) | United States | $0.897B | 23.57 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.794B | 20.23 |
| Cerus (CERS) | United States | $0.769B | 0.00 |
| MacroGenics (MGNX) | United States | $0.737B | 0.00 |
| Quanterix (QTRX) | United States | $0.702B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.648B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.626B | 37.08 |
| Surmodics (SRDX) | United States | $0.601B | 114.26 |
| OraSure Technologies (OSUR) | United States | $0.446B | 20.63 |
| Meridian Bioscience (VIVO) | United States | $0.432B | 13.48 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.423B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.376B | 123.63 |
| United Health Products (UEEC) | United States | $0.350B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.349B | 25.56 |
| Zynex (ZYXI) | United States | $0.345B | 36.62 |
| Owens & Minor (OMI) | United States | $0.306B | 9.17 |
| Bovie Medical (APYX) | United States | $0.251B | 0.00 |
| Vapotherm (VAPO) | United States | $0.244B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.155B | 0.00 |
| Chimerix (CMRX) | United States | $0.153B | 0.00 |
| Fonar (FONR) | United States | $0.152B | 8.01 |
| Rockwell Medical (RMTI) | United States | $0.152B | 0.00 |
| Female Health (VERU) | United States | $0.123B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.099B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.097B | 0.00 |
| United-Guardian (UG) | United States | $0.087B | 20.65 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.057B | 0.00 |
| Surface Oncology (SURF) | United States | $0.055B | 0.00 |
| Nephros (NEPH) | United States | $0.054B | 0.00 |
| MRI INTERVENTNS (MRIC) | United States | $0.048B | 0.00 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.041B | 14.17 |
| Senestech (SNES) | United States | $0.039B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.013B | 0.00 |
| Myomo (MYO) | United States | $0.011B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.011B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.010B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.006B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.005B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.003B | 0.00 |
